This Article Full Text (PDF) All Versions of this Article: theoncologist.2008-0003v1 13/9/1021    most recent eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kabbinavar, F. F. Articles by Hurwitz, H. I. Search for Related Content PubMed PubMed Citation Articles by Kabbinavar, F. F. Articles by Hurwitz, H. I.

Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

^aUniversity of California at Los Angeles (UCLA) School of Medicine, Los Angeles, California, USA; ^bGenentech, Inc., South San Francisco, California, USA; ^cCenter on Outcomes, Research and Education, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois, USA; ^dDuke University, Durham, North Carolina, USA

Key Words. Colorectal cancer • Quality of life • Fluorouracil • Monoclonal antibodies • Bevacizumab • Angiogenesis inhibitors

Correspondence: Fairooz Kabbinavar, M.D., Division of Hematology/Oncology, UCLA School of Medicine, 10945 LeConte Avenue, Suite 2333D, Los Angeles, California 90095-7059, USA. Telephone: 310-206-3921; Fax: 310-267-0151; e-mail: fkabbina{at}mednet.ucla.edu

Received January 2, 2008; accepted for publication July 18, 2008.

ABSTRACT

Purpose. To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies.

Patients and Methods. Prespecified HRQoL endpoints in the phase II (Study 2192) and phase III (Study 2107) studies were time to deterioration in HRQoL, measured by the Functional Assessment of Cancer Therapy–Colorectal (FACT-C) Colorectal Cancer Subscale (CCS), Trial Outcome Index (TOI-C), and FACT-C total score. Time to deterioration in HRQoL was evaluated for patients with baseline and postbaseline assessments, using the stratified log-rank test.

Results. In the pivotal phase III trial, HRQoL baseline and postbaseline CCS scores were available for 127 patients receiving irinotecan, 5-FU, and leucovorin (LV) (IFL) and 122 patients receiving IFL plus BV. The time to deterioration in HRQoL did not differ significantly between treatment groups as measured by the CCS, TOI-C, or FACT-C total score. In the phase II study, baseline and postbaseline CCS scores were available for 77 and 89 patients receiving 5-FU and LV and 5-FU and LV plus BV, respectively. In that study, the time to deterioration in HRQoL was similar between groups as measured by the CCS and TOI-C scores, but was significantly longer in the 5-FU and LV plus BV arm than in the 5-FU and LV plus placebo arm for the FACT-C total score.

Conclusions. When added to 5-FU chemotherapy, BV significantly prolonged overall survival and progression-free survival without compromising HRQoL.